Diabetes

Anagliptin effect on LDL in T2DM via ApoB-100 synthesis

(HealthDay)—In patients with type 2 diabetes being treated with a dipeptidyl peptidase-4 inhibitor (DPP4-I), use of anagliptin (ANA) may improve low-density lipoprotein cholesterol (LDL-C) levels, with the effect mediated, ...

Cardiology

ApoB levels more closely tied to reduced CVD events than LDL

(HealthDay)—Clinical benefit of reduced low-density lipoprotein cholesterol (LDL-C) levels may depend on the corresponding reduction in apolipoprotein B (apoB)-containing lipoprotein particles, according to a study published ...

Cardiology

Gene therapy using 'junk DNA' could lower risk for heart disease

Scientists from UCLA and the Howard Hughes Medical Institute successfully used a gene that suppresses cholesterol levels as part of a treatment to reduce plaque in mice with a disorder called familial hypercholesterolemia. ...

Cardiology

More evidence evolocumab exceeds cost-effectiveness

(HealthDay)—At its current price, the addition of evolocumab to standard therapy in patients with atherosclerotic cardiovascular disease generally exceeds accepted cost-effectiveness thresholds, according to a study published ...

Cardiology

Evolocumab doesn't affect cognition when added to statins

(HealthDay)—There is no significant difference in cognitive function for patients treated with evolocumab or placebo added to statin therapy, according to a study published in the Aug. 17 issue of the New England Journal ...

Cardiology

New model predicts mortality in stable coronary heart disease

(HealthDay)—A biomarker-based model provides a new tool for the prediction of cardiovascular (CV) death in patients with stable coronary heart disease (CHD), according to a study published in the Aug. 15 issue of the Journal ...

page 15 from 26